The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study
Open accessAbstract
We performed a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose-response study of the efficacy and safety of the oral administration of PG-116800, a matrix metalloproteinase (MMP) inhibitor, in patients with mild to moderate knee osteoarthritis. The primary efficacy endpoints included the progression of joint space narrowing in the osteoarthritic knee, as measured by microfocal radiography with fluoroscopic positioning, and the reduction of symptoms (pain and stiffness) and/or the improvement of function, as measured by the Western Ontario and McMaster Universities osteoarthritis index (WOMAC). Four hundred and one patients were randomly assigned to either placebo (n= 80) or one of fourdoses of PG-116800: 25 mg (n= 81), 50 mg (n= 80), 100 mg (n= 80), or 200 mg (n= 80) taken twice daily for 12 months. During the study, the 200-mg dose was discontinued based on an increased frequency of musculoskeletal adverse effects. After 1 year of treatment, no statistically significant difference was observed between placebo and PG-116800 with regard to mean changes in minimum joint space width of the knee or to WOMAC scores. The most frequent adverse effect was arthralgia (35%). Twenty-three percent of evaluable patients had at least a 30% decrease from baseline of at least onerange-of-motion measurement of either shoulder at a follow-up visit. The percentage of patients with reduction in range of motion was significantly greater in the twohighest dose groups relative to placebo. Thirteen percent of patients, half of whom were in the 200-mg group, reported hand adverse events (oedema, palmar fibrosis, Dupuytren contracture, or persistent tendon thickness or nodules). The threemost frequent shoulder adverse events were reversible arthralgia, stiffness, and myalgia, which mostly affected the twohighest dose groups. The unfavorable risk-benefit balance of the MMP inhibitor PG-116800 in patients with knee osteoarthritis precludes further development of the compound for this indication. This study adds to the weight of evidence suggesting that side effect profiles of MMP inhibitors in general make them unsuitable for use in osteoarthritis. Trial Registration: ClinicalTrials.gov NCT00041756.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052771 · Cited by 1,329
Cited by
Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., & Carr, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60802-3 · Cited by 3,151
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01330-w · Cited by 1,194
Little, C. B., Barai, A., Burkhardt, D., Smith, S. M., Fosang, A. J., Werb, Z., Shah, M., & Thompson, E. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25002 · Cited by 642
Current research on pharmacologic and regenerative therapies for osteoarthritis
Zhang, W., Ouyang, H., Dass, C. R., & Xu, J. (2016) · Bone Research · doi:10.1038/boneres.2015.40 · Cited by 495
Current understanding of osteoarthritis pathogenesis and relevant new approaches
Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., Wang, H., Xing, L., & Chen, D. (2022) · Bone Research · doi:10.1038/s41413-022-00226-9 · Cited by 437
Emerging pharmaceutical therapies for osteoarthritis
Latourte, A., Kloppenburg, M., & Richette, P. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00518-6 · Cited by 418
Karsdal, M. A., Michaelis, M., Ladel, C., Siebuhr, A. S., Bihlet, A. R., Andersen, J. R., Guehring, H., Christiansen, C., Bay-Jensen, A. C., & Kraus, V. B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.07.017 · Cited by 381
Senescent cells and osteoarthritis: a painful connection
Jeon, O. H., David, N., Campisi, J., & Elisseeff, J. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95147 · Cited by 356
Peng, Z., Sun, H., Bunpetch, V., Koh, Y., Wen, Y., Wu, D., & Ouyang, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120555 · Cited by 347
Gregori, D., Giacovelli, G., Minto, C., Barbetta, B., Gualtieri, F., Azzolina, D., Vaghi, P., & Rovati, L. C. (2018) · JAMA · doi:10.1001/jama.2018.19319 · Cited by 337
Cartilage damage in osteoarthritis and rheumatoid arthritis—two unequal siblings
Pap, T., & Korb-Pap, A. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.95 · Cited by 317
Recent advances in the treatment of osteoarthritis
Grässel, S., & Muschter, D. (2020) · F1000Research · doi:10.12688/f1000research.22115.1 · Cited by 307
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions
Cho, Y., Jeong, S., Kim, H., Kang, D., Lee, J., Kang, S.-B., & Kim, J.-H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00710-y · Cited by 296
Pharmacologic therapy for osteoarthritis—the era of disease modification
Hunter, D. J. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.178 · Cited by 288
ADAMTS proteins in human disorders
Mead, T. J., & Apte, S. S. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.06.002 · Cited by 279
Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism
Goldring, M. B., Otero, M., Tsuchimochi, K., Ijiri, K., & Li, Y. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.098764 · Cited by 262
Ritzman, A. M., Hughes-Hanks, J. M., Blaho, V. A., Wax, L. E., Mitchell, W. J., & Brown, C. R. (2010) · Infection and Immunity · doi:10.1128/iai.00798-10 · Cited by 123
Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis
Colazo, J. M., Hoogenboezem, E. N., Keech, M. C., Francini, N., Shah, V., Yu, F., Lo, J. H., Sorets, A. G., McCune, J. T., Cho, H., et al. (2023) · doi:10.1101/2023.05.31.542971 · Cited by 11
Greaves, P. (2012) · Histopathology of Preclinical Toxicity Studies · doi:10.1016/b978-0-444-53856-7.00002-6 · Cited by 5
Metadata
- Authors
- Krzeski, P., Buckland-Wright, C., Bálint, G., Cline, G. A., Stoner, K., Lyon, R., Beary, J., Aronstein, W. S., & Spector, T. D.
- Venue
- Arthritis Research & Therapy
- Published
- 2007-10-24
- Volume
- 9
- Issue
- 5
- Pages
- R109-R109
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2172129201
- Cited by
- 203
- References
- 2
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.